

SISAQOL-IMI Consortium Members

Stakeholder Group	Organizations (alphabetical order)	Country
Academic		
	Amsterdam University Medical Center	NL
	Clinical Hospital Center Rijeka	HR
	Complejo Hospitalario de Navarra	ES
	Duke University School of Medicine	US
	Institut Hospital del Mar d'Investigacions Mèdiques	ES
	Johns Hopkins University (representing Patient-Reported Outcomes Tools: Engaging Users and Stakeholders [PROTEUS] and Patient-Reported Outcomes Data Presentation Stakeholder Group)	US
	Katholieke Universiteit Leuven	BE
	Leiden University Medical Center	NL
	Medical University of Innsbruck	AT
	Oslo University Hospital	NO
	Region Hovedstaden	DK
	The Symptoms Tool Executive Committee of the University of Texas MD Anderson Cancer Center (The Texas Group)	US
	University Health Network	CA
	University of Birmingham	UK
	University of Freiburg	DE
	University of Ghent	BE
	University of Leeds	UK
Industry		
	AbbVie	US/DE
	Bayer	US/DE
	Boehringer Ingelheim	DE
	Merck Healthcare KGaA/EMD Serono	DE/US
	Pfizer	US/UK
Non-Profit/Cancer Organizations		
	American Society of Clinical Oncology	US
	Critical Path Institute	US
	EORTC	BE
	European Society for Medical Oncology	CH
	National Cancer Center Hospital (Japan Clinical Oncology Group)	JP
	National Cancer Institute	US
	Queen's University at Kingston (CCTG)	CA
	University of Sydney (Sydney Quality of Life Office)	AU
Small to Mid-Size Enterprise/Contract Research Organization		

	Adelphi Values	UK
	Evaluation Software Development	AT
	Modus Outcomes	FR
	Patient Relevant Evidence	US
Regulatory		
	European Medicines Agency	EU (NL)
	Health Canada	CA
	Medicines and Healthcare Products Regulatory Agency	UK
	FDA	US
Health Technology Assessment		
	Institute for Quality and Efficiency in Health Care	DE
	Norwegian Medicines Agency	NO
Patients' Representative		
	Myeloma Patients Europe (on behalf of the Workgroup of European Cancer Advocacy Networks [WECAN], consisting of 23 Pan-European cancer patient organizations.)	BE

SISAQOL-IMI Key Contributors

Individual key contributors	Organisations	Country
• Madeline Pe • Ahu Alanya • Corneel Coens	EORTC	BE
• Saskia Le Cessie • Martin Taphoorn	Leiden University Medical Center	NL
• Johannes Giesinger • Bernhard Holzner • Lisa Wintner	Medical University of Innsbruck	AT
• Kristin Bjordal	Oslo University Hospital	NO
• Silene ten Seldam	Myeloma Patients Europe (on behalf of WECAN)	BE
• Anders Ingelgaard	Boehringer Ingelheim	DE
• Elektra Papadopoulos	AbbVie	US/DE
• Michael Schlichting • Vivek Pawar	Merck Healthcare KGaA/EMD Serono	DE/US
• Satrajit Roychoudhury • Jane Chang • Paul Cislo • Joseph Cappelleri	Pfizer	US/UK
• Vishal Bhatnagar • Mallorie Fiero	FDA	US
• Chantal Quinten	European Medicines Agency	EU (NL)

• Maxime Sasseville	Health Canada	CA
• Khadija Rantell	Medicines and Healthcare Products Regulatory Agency	UK
• Anja Schiel	Norwegian Medicines Agency	NO